Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab (KN035) plus lenvatinib in advanced solid tumors
CTR20212002Phase 2Active
- Sponsor
- Sichuan Sigmaker Pharmaceutical
- Start
- Nov 2021
- Modality
- Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab, lenvatinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), sponsored by Sichuan Sigmaker Pharmaceutical. Started Nov 2021; status: active.
02
Drugs
envafolimablenvatinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20212002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212002.